Praliciguat
Phase 2Small molecule
Praliciguat is one of 10 small molecule programs targeting Focal Segmental Glomerulosclerosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Focal Segmental Glomerulosclerosis
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Empaveli
Apellis PharmaceuticalsApproved
Filspari
TTravere Therapeutics, Inc.
Phase 3
Prograf
VVeloxis Pharmaceuticals
Preclinical
Praliciguat
AAkebia Therapeutics
Phase 2
Mannac
LLeadiant Biosciences, Inc.
Phase 2
FK506
AstellasPreclinical
Tripterygium Wilfordii
ZZhi-Hong Liu, M.D.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Praliciguat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAkebia Therapeutics